A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaChan Y. Cheah, John F. Seymour, Alexander George et al.|British Journal of Cancer|2014Cited by 132
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human TrialConstantine S. Tam, Andrew W. Roberts, Andrew Grigg et al.|Blood|2015Cited by 111